BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//ZContent.net//ZapCalLib 1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
SUMMARY:The Promise of Using Platinum(II) Supramolecular Coordination Compl
 exes for Photodynamic Therapy (PDT) Applications
LOCATION:Chemistry A101
TZID:America/Denver
DTSTART:20191001T000000
UID:2026-05-16-08-59-52@natsci.colostate.edu
DTSTAMP:20260516T085952
Description:Literature Seminar\n\nPhotodynamic therapy (PDT) is an emerging
  cancer treatment based on the interactions between light\, a photosensiti
 zing drug and oxygen\, which create reactive oxygen species (ROS)\, killin
 g cells in a localized region. Although PDT is efficient for the local des
 truction of tumors\, the treatment is still ineffective in systemic tumor 
 elimination\, so other treatment conditions combined with PDT are utilized
  for maximum effectiveness. PDT has become of interest as a potential part
 ner of chemotherapy when recent research has shown that the two treatments
  combined show a synergistic effect against cancer. To take advantage of t
 he potential combination between chemotherapy and PDT\, there has been a f
 ocus on exploring compounds that are designed to improve both treatments s
 imultaneously. Supramolecular coordination complexes (SCCs) have been of p
 articular interest\, combining the anticancer properties of organoplatinum
 (II) with the fluorescence properties of diverse photosensitizing agents v
 ia the spontaneous formation of metal-ligand bonds. The fluorescent proper
 ties of a photosensitizer are altered by a change in the ligand and theref
 ore medical research has been exploring new fluorescent ligands to bind to
  the platinum core. Herein\, the properties of two potential fluorescent l
 igands\, boron dipyrromethene (BODIPY) and tetra(4-pyridyl)porphyrin (TPP)
  were investigated for their anticancer applications in combination with o
 rganoplatinum(II) due to the rare occurrence of highly fluorescent SCCs wi
 th BODIPY ligands and the need to further improve SCCs with commonly used 
 porphyrin-based TPP ligands (1\,2). The results showed that the combinatio
 n of organoplatinum(II) and both BODIPY and TPP ligands were found to impr
 ove the combinational treatment of chemotherapy and photodynamic therapy\;
  however\, SCCs with TPP ligands were found to be more effective due to hi
 gher singlet oxygen (1O2) and quantum yields and reduced cytotoxicity in v
 ivo (1\,2). This shows that TPP ligands were effective for photochemothera
 py and provides a general scaffold to further develop multifunctional agen
 ts for photodynamic therapy applications.\n\n(1) Zhou\, J.\; Zhang\, Y.\; 
 Yu\, G.\; Crawley\, M. R.\; Fulong\, C. R. P.\; Friedman\, A. E.\; Sengupt
 a\, S.\; Sun\, J.\; Li\, Q.\; Huang\, F.\; Cook\, T. R. Highly Emissive Se
 lf-Assembled BODIPY-Platinum Supramolecular Triangles. J. Am. Chem. Soc. 2
 018\, 140\, 7730−7736. \nDOI: 10.1021/jacs.8b04929. \n(2) Yu\, G.\; Yu\,
  S.\; Saha\, M. L.\; Zhou\, J.\; Cook\, T. R.\; Yung\, B. C.\; Chen\, J.\;
  Mao\, Z.\; Zhang\, F.\; Zhou\, Z.\; Liu\, Y.\; Shao\, L.\; Wang\, S.\; Ga
 o\, C.\; Huang\, F.\; Stang\, P. J.\; Chen\, X. 1. A discrete organoplatin
 um(II) metallacage as a multimodality theranostic platform for cancer phot
 ochemotherapy. \nNature Comm. DOI: 10.1038/s41467-018-06574-7. 4:00 pm
END:VEVENT
END:VCALENDAR